-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In March of Yangchun, the "CSCO Anti-Lymphoma Alliance Tour-Tianjin Station" meeting was successfully held yesterday (March 27).
The meeting was hosted by the CSCO Anti-Lymphoma Alliance, Department of Lymphoma, Tianjin Medical University Cancer Hospital and China Co-organized by the Lymphoma Diagnosis and Treatment Center of the Hematology Hospital of the Academy of Medical Sciences and co-organized by the Tianjin Medical and Health Association.
Many experts in the lymphoma field from all over the country conducted in-depth analysis and intense discussions on the hot and difficult issues in the diagnosis and treatment of lymphoma.
This conference adopted a combination of online and offline methods.
The offline academic atmosphere was strong.
The total number of online viewers reached 26,768.
At the same time, the highest online number was 945, which attracted many domestic workers in the lymphoma field and provided comprehensive assistance.
Improve the level of medical workers in the field of lymphoma in China, and ultimately benefit more patients.
Opening remarks At the beginning of the meeting, the executive chairman of the conference, Professor Zhang Huilai from Tianjin Medical University Cancer Hospital, and Professor Zou Dehui from the Hospital of Hematology, Chinese Academy of Medical Sciences, served as the chairpersons, and jointly extended a warm welcome to the participants.
Afterwards, Professor Ma Jun from Harbin Institute of Hematology and Tumor and Professor Zhu Jun from Peking University Cancer Hospital respectively delivered opening remarks online.
Professor Ma Jun said that the current incidence of lymphoma in my country is high, and the cure rate is still very low.
It requires the joint efforts of various hospitals and centers to achieve the goal of an overall cancer 5-year survival rate of 15% as soon as possible, and promote the "Healthy China 2030 Plan".
Landing will benefit patients.
It is expected that the prevention and treatment of lymphoma in China will reach the world-class level.
In the speech session of Professor Zhu Jun, Professor Zhu Jun said that lymphoma doctors have a long way to go.
He hopes that hospitals and centers will adhere to multidisciplinary cooperation, establish a specialist medical consortium, and further promote the development of standardized lymphoma diagnosis and treatment.
He also wished this time.
The conference was successfully held. Academic Lecture: Lymphoma Targeting and Cellular Therapy Review and Prospects Speaker: Professor Ma Jun from Harbin Institute of Hematology and Tumor Chair: Professor Zou Dehui from the Hospital of Hematology, Chinese Academy of Medical Sciences Professor Ma Jun gave a wonderful lecture on the targeted therapy of lymphoma.
Professor Ma Jun said that antibody-based macromolecular drugs are widely used.
The application of classic monoclonal antibodies represented by rituximab and otuzumab (GA101) has created a new era of immunotherapy.
Since then, bispecific antibodies and antibody-conjugated drugs have been approved in China successively and have been used in clinical practice.
Small molecule drugs targeting intracellular signaling pathways and microenvironment are new and beneficial weapons for anti-tumor therapy.
Finally, Professor Ma Jun briefly introduced the research status of new treatment methods.
There are many ongoing research projects for CAR-T therapy in China, and the results are worth looking forward to.
At the same time, Professor Ma Jun mentioned that cell therapy, tumor vaccines and gene editing technologies have all brought new hope for the treatment of lymphoma.
Follicular lymphoma treatment puzzle Speaker: Professor Liu Lihong from the Fourth Hospital of Hebei Medical University Chair: Professor Liu Lihong from Shanxi Cancer Hospital said that with the development of new drugs, the overall survival period (OS) of follicular lymphoma (FL) ) Significant improvement, the 10-year OS rate can reach 80%, but after transformation (tDLBCL, cDLBCI/FL) and disease progression within 24 months (POD24), the prognosis of patients is poor and the survival period is significantly shortened.
Transformed FL has more sources of germinal centers, more double-hit probability, more adverse prognostic gene expressions (such as tp53), treatment should be aimed at pursuing complete remission (CR), first-line transplantation increases the depth of remission and increases the CR rate , Survival benefits can be obtained, but it is still controversial whether to carry out maintenance treatment afterwards.
At present, how to identify those patients with early progress and transformation, the current predictive scoring system has its own advantages and disadvantages, and in the era of new drugs, the prognosis of patients after treatment with new drugs cannot be predicted.
New progress in targeted therapy for DLBCL Speaker: Professor Li Zhiming from Sun Yat-sen University Cancer Center Chair: Professor Liu Yao from Chongqing University Cancer Hospital, Professor Li Zhiming said that for B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL) Targeted new drugs are being studied, and there is a lot of room for the combination of traditional chemotherapy, targeted therapy, and immunotherapy.
Therefore, although it has entered the age of immunotherapy, targeted therapy is still an important treatment method.
Standardized or individualized first-line treatment of DLBCL? Speaker: Professor Zhou Hui from Hunan Cancer Hospital Host: Professor Li Zengjun from Shandong Cancer Hospital The first-line standardized treatment of DLBCL is the 6-8 cycle R-CHOP-21 regimen; some patients need to be based on factors such as their age, type and stage.
Choose other more suitable treatment options.
Irregular treatment may cause drug resistance in patients and affect their prognosis.
However, because DLBCL is a highly aggressive and heterogeneous malignant lymphatic pain, with the further understanding of its molecular biology and genetics, it is particularly important to formulate individualized treatment plans based on its classification.
Choosing a treatment plan based on stratified factors such as classification and prognosis is an important rule followed in the treatment of DLBCL.
In addition, in the process of DLBCL treatment, it is very necessary to carry out a combination of standardized and individualized treatment plans.
How to combine standardized treatment principles and develop individualized treatment work on this basis is the focus of current research.
Thinking about the diagnosis and treatment status of peripheral T-cell lymphoma Speaker: Professor Li Wenyu, the First Affiliated Hospital of South China University of Technology Chair: Professor Hua Luoming, Affiliated Hospital of Hebei University Patients with stage I-II peripheral T-cell lymphoma (PTCL) after CHOP chemotherapy, The 5-year progression-free survival (PFS) rate can reach more than 50%.
For patients with relapsed and refractory (R/R) PTCL, the long-term survival rate after allogeneic hematopoietic stem cell transplantation (allo-HSCT) can reach more than 60%.
In addition, new drugs such as CD30 monoclonal antibody, HDAC inhibitors, azacitidine, PI3K inhibitors, etc.
have achieved remarkable clinical effects in PTCL, and we look forward to the advancement of clinical research. Current status of clinical trials of bispecific antibodies in the treatment of lymphoma Speaker: Professor Zhu Jun from Peking University Cancer Hospital Chair: Professor Zhang Huilai from Tianjin Medical University Cancer Hospital Professor Zhu Jun said that bispecific antibodies are monoclonal antibodies that recognize two targets at the same time and play a combined role Drugs improve the selectivity and affinity of monoclonal antibodies, target effector cells to tumor cells, improve drug safety and effectiveness, and reduce development costs.
Subsequently, Professor Zhu Jun introduced several domestic and foreign clinical trials and related treatments using bispecific antibodies to treat lymphoma.
Finally, Professor Zhu Jun said that the diagnosis and treatment of lymphoma has entered a new era, and relevant workers should explore a new model of standardized diagnosis and treatment, promote the development of multidisciplinary specialization, advocate new clinical trials of drugs, and emphasize the quality of life and potency ratio.
New progress in diagnosis and treatment of typical Hodgkin’s lymphoma Speaker: Professor Qian Zhengzi from Tianjin Medical University Cancer Hospital Chair: Professor Wu Huijing from Hubei Cancer Hospital Professor Qian Zhengzi said that the chemotherapy regimen for Hodgkin’s lymphoma (HL) is stratified and precise The current direction is to maintain the healing effect under the guidance of PET and reduce the toxicity of the treatment.
In addition, the "sequelae" after HL is cured have become a problem that must be paid attention to in clinical work, especially the prevention and management of secondary tumors and cardiovascular diseases.
For patients with R/R HL, hematopoietic stem cell transplantation, verbutuximab (BV), and immune checkpoint inhibitors are important treatment options.
Nivolumab combined with BV in the treatment of R/R classic HL (cHL) can achieve a higher CR rate (62%), and it is still effective for patients who have previously received BV treatment.
The safety is acceptable and deserves further study.
Professor Qian Zhengzi said that the future treatment trend of cHL is the combination of traditional therapies and targeted therapies, such as BV+AVD, PD-1 antibody+chemotherapy, and CD30-targeted cellular immunotherapy.
The status of DLBCL transplantation in the CAR-T era Speaker: Professor Liu Wei from the Hematology Hospital of the Chinese Academy of Medical Sciences Chair: Professor Liu Wei from the Sino-Japanese Friendship Hospital of Jilin University said that for patients with R/R large B-cell lymphoma (LBCL), If CR is obtained after salvage chemotherapy, ASCT is still the first choice; if salvage chemotherapy does not reach CR (PR/SD/PD), CAR-T treatment can be performed as soon as possible.
So, can CAR-T treatment replace ASCT as the first-line treatment of DLBCL? Professor Liu Wei said that the results of clinical trials have yet to be confirmed.
It is still uncertain whether allo-HSCT is sequential after CAR-T treatment is effective.
Patients who still maintain the efficacy (especially CR) at 3 months after CAR-T treatment can be observed and followed up.
However, the preliminary study of ASCT combined with CAR-T therapy shows that the safety is controllable, the proportion of continuous CR at 1-year follow-up is higher, and the efficacy is better than CAR-T therapy alone.
In addition, Professor Wang Yalan from Baotou Cancer Hospital, Inner Mongolia, Professor Zhang Huilai from Tianjin Medical University Cancer Hospital, Professor Sun Ying from Chifeng City Hospital, Professor Jiao Zongjiu from Xingtai People's Hospital, Professor Wang Yinan from Tangshan People's Hospital, Professor Suo Xiaohui from Handan Central Hospital, Professor Li Lanfang from Tianjin Medical University Cancer Hospital, Professor Meng Xiangling from Cangzhou Integrated Traditional Chinese and Western Medicine Hospital, Professor Zhao Yue from the Fourth Hospital of Qinhuangdao City, and Professor Qiu Lihua from Tianjin Medical University Cancer Hospital made brief comments on the special report of the conference and had wonderful interactions with the speakers.
Conference summary Professor Zhang Huilai said that in recent years, the diagnosis and treatment of lymphoma has progressed rapidly, and the specialized construction and overall management of lymphoma in each center have been excellent.
Professor Zhang Huilai expects that Tianjin and other cancer hospitals and centers across the country can provide standardized diagnosis and treatment of lymphoma to benefit patients.
Finally, Professor Zhang Huilai expressed his gratitude to the experts and colleagues who participated in the meeting for their support and assistance, and congratulated the successful holding of the meeting.
Stamp "Read the original" to watch the replay of the conference
The meeting was hosted by the CSCO Anti-Lymphoma Alliance, Department of Lymphoma, Tianjin Medical University Cancer Hospital and China Co-organized by the Lymphoma Diagnosis and Treatment Center of the Hematology Hospital of the Academy of Medical Sciences and co-organized by the Tianjin Medical and Health Association.
Many experts in the lymphoma field from all over the country conducted in-depth analysis and intense discussions on the hot and difficult issues in the diagnosis and treatment of lymphoma.
This conference adopted a combination of online and offline methods.
The offline academic atmosphere was strong.
The total number of online viewers reached 26,768.
At the same time, the highest online number was 945, which attracted many domestic workers in the lymphoma field and provided comprehensive assistance.
Improve the level of medical workers in the field of lymphoma in China, and ultimately benefit more patients.
Opening remarks At the beginning of the meeting, the executive chairman of the conference, Professor Zhang Huilai from Tianjin Medical University Cancer Hospital, and Professor Zou Dehui from the Hospital of Hematology, Chinese Academy of Medical Sciences, served as the chairpersons, and jointly extended a warm welcome to the participants.
Afterwards, Professor Ma Jun from Harbin Institute of Hematology and Tumor and Professor Zhu Jun from Peking University Cancer Hospital respectively delivered opening remarks online.
Professor Ma Jun said that the current incidence of lymphoma in my country is high, and the cure rate is still very low.
It requires the joint efforts of various hospitals and centers to achieve the goal of an overall cancer 5-year survival rate of 15% as soon as possible, and promote the "Healthy China 2030 Plan".
Landing will benefit patients.
It is expected that the prevention and treatment of lymphoma in China will reach the world-class level.
In the speech session of Professor Zhu Jun, Professor Zhu Jun said that lymphoma doctors have a long way to go.
He hopes that hospitals and centers will adhere to multidisciplinary cooperation, establish a specialist medical consortium, and further promote the development of standardized lymphoma diagnosis and treatment.
He also wished this time.
The conference was successfully held. Academic Lecture: Lymphoma Targeting and Cellular Therapy Review and Prospects Speaker: Professor Ma Jun from Harbin Institute of Hematology and Tumor Chair: Professor Zou Dehui from the Hospital of Hematology, Chinese Academy of Medical Sciences Professor Ma Jun gave a wonderful lecture on the targeted therapy of lymphoma.
Professor Ma Jun said that antibody-based macromolecular drugs are widely used.
The application of classic monoclonal antibodies represented by rituximab and otuzumab (GA101) has created a new era of immunotherapy.
Since then, bispecific antibodies and antibody-conjugated drugs have been approved in China successively and have been used in clinical practice.
Small molecule drugs targeting intracellular signaling pathways and microenvironment are new and beneficial weapons for anti-tumor therapy.
Finally, Professor Ma Jun briefly introduced the research status of new treatment methods.
There are many ongoing research projects for CAR-T therapy in China, and the results are worth looking forward to.
At the same time, Professor Ma Jun mentioned that cell therapy, tumor vaccines and gene editing technologies have all brought new hope for the treatment of lymphoma.
Follicular lymphoma treatment puzzle Speaker: Professor Liu Lihong from the Fourth Hospital of Hebei Medical University Chair: Professor Liu Lihong from Shanxi Cancer Hospital said that with the development of new drugs, the overall survival period (OS) of follicular lymphoma (FL) ) Significant improvement, the 10-year OS rate can reach 80%, but after transformation (tDLBCL, cDLBCI/FL) and disease progression within 24 months (POD24), the prognosis of patients is poor and the survival period is significantly shortened.
Transformed FL has more sources of germinal centers, more double-hit probability, more adverse prognostic gene expressions (such as tp53), treatment should be aimed at pursuing complete remission (CR), first-line transplantation increases the depth of remission and increases the CR rate , Survival benefits can be obtained, but it is still controversial whether to carry out maintenance treatment afterwards.
At present, how to identify those patients with early progress and transformation, the current predictive scoring system has its own advantages and disadvantages, and in the era of new drugs, the prognosis of patients after treatment with new drugs cannot be predicted.
New progress in targeted therapy for DLBCL Speaker: Professor Li Zhiming from Sun Yat-sen University Cancer Center Chair: Professor Liu Yao from Chongqing University Cancer Hospital, Professor Li Zhiming said that for B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL) Targeted new drugs are being studied, and there is a lot of room for the combination of traditional chemotherapy, targeted therapy, and immunotherapy.
Therefore, although it has entered the age of immunotherapy, targeted therapy is still an important treatment method.
Standardized or individualized first-line treatment of DLBCL? Speaker: Professor Zhou Hui from Hunan Cancer Hospital Host: Professor Li Zengjun from Shandong Cancer Hospital The first-line standardized treatment of DLBCL is the 6-8 cycle R-CHOP-21 regimen; some patients need to be based on factors such as their age, type and stage.
Choose other more suitable treatment options.
Irregular treatment may cause drug resistance in patients and affect their prognosis.
However, because DLBCL is a highly aggressive and heterogeneous malignant lymphatic pain, with the further understanding of its molecular biology and genetics, it is particularly important to formulate individualized treatment plans based on its classification.
Choosing a treatment plan based on stratified factors such as classification and prognosis is an important rule followed in the treatment of DLBCL.
In addition, in the process of DLBCL treatment, it is very necessary to carry out a combination of standardized and individualized treatment plans.
How to combine standardized treatment principles and develop individualized treatment work on this basis is the focus of current research.
Thinking about the diagnosis and treatment status of peripheral T-cell lymphoma Speaker: Professor Li Wenyu, the First Affiliated Hospital of South China University of Technology Chair: Professor Hua Luoming, Affiliated Hospital of Hebei University Patients with stage I-II peripheral T-cell lymphoma (PTCL) after CHOP chemotherapy, The 5-year progression-free survival (PFS) rate can reach more than 50%.
For patients with relapsed and refractory (R/R) PTCL, the long-term survival rate after allogeneic hematopoietic stem cell transplantation (allo-HSCT) can reach more than 60%.
In addition, new drugs such as CD30 monoclonal antibody, HDAC inhibitors, azacitidine, PI3K inhibitors, etc.
have achieved remarkable clinical effects in PTCL, and we look forward to the advancement of clinical research. Current status of clinical trials of bispecific antibodies in the treatment of lymphoma Speaker: Professor Zhu Jun from Peking University Cancer Hospital Chair: Professor Zhang Huilai from Tianjin Medical University Cancer Hospital Professor Zhu Jun said that bispecific antibodies are monoclonal antibodies that recognize two targets at the same time and play a combined role Drugs improve the selectivity and affinity of monoclonal antibodies, target effector cells to tumor cells, improve drug safety and effectiveness, and reduce development costs.
Subsequently, Professor Zhu Jun introduced several domestic and foreign clinical trials and related treatments using bispecific antibodies to treat lymphoma.
Finally, Professor Zhu Jun said that the diagnosis and treatment of lymphoma has entered a new era, and relevant workers should explore a new model of standardized diagnosis and treatment, promote the development of multidisciplinary specialization, advocate new clinical trials of drugs, and emphasize the quality of life and potency ratio.
New progress in diagnosis and treatment of typical Hodgkin’s lymphoma Speaker: Professor Qian Zhengzi from Tianjin Medical University Cancer Hospital Chair: Professor Wu Huijing from Hubei Cancer Hospital Professor Qian Zhengzi said that the chemotherapy regimen for Hodgkin’s lymphoma (HL) is stratified and precise The current direction is to maintain the healing effect under the guidance of PET and reduce the toxicity of the treatment.
In addition, the "sequelae" after HL is cured have become a problem that must be paid attention to in clinical work, especially the prevention and management of secondary tumors and cardiovascular diseases.
For patients with R/R HL, hematopoietic stem cell transplantation, verbutuximab (BV), and immune checkpoint inhibitors are important treatment options.
Nivolumab combined with BV in the treatment of R/R classic HL (cHL) can achieve a higher CR rate (62%), and it is still effective for patients who have previously received BV treatment.
The safety is acceptable and deserves further study.
Professor Qian Zhengzi said that the future treatment trend of cHL is the combination of traditional therapies and targeted therapies, such as BV+AVD, PD-1 antibody+chemotherapy, and CD30-targeted cellular immunotherapy.
The status of DLBCL transplantation in the CAR-T era Speaker: Professor Liu Wei from the Hematology Hospital of the Chinese Academy of Medical Sciences Chair: Professor Liu Wei from the Sino-Japanese Friendship Hospital of Jilin University said that for patients with R/R large B-cell lymphoma (LBCL), If CR is obtained after salvage chemotherapy, ASCT is still the first choice; if salvage chemotherapy does not reach CR (PR/SD/PD), CAR-T treatment can be performed as soon as possible.
So, can CAR-T treatment replace ASCT as the first-line treatment of DLBCL? Professor Liu Wei said that the results of clinical trials have yet to be confirmed.
It is still uncertain whether allo-HSCT is sequential after CAR-T treatment is effective.
Patients who still maintain the efficacy (especially CR) at 3 months after CAR-T treatment can be observed and followed up.
However, the preliminary study of ASCT combined with CAR-T therapy shows that the safety is controllable, the proportion of continuous CR at 1-year follow-up is higher, and the efficacy is better than CAR-T therapy alone.
In addition, Professor Wang Yalan from Baotou Cancer Hospital, Inner Mongolia, Professor Zhang Huilai from Tianjin Medical University Cancer Hospital, Professor Sun Ying from Chifeng City Hospital, Professor Jiao Zongjiu from Xingtai People's Hospital, Professor Wang Yinan from Tangshan People's Hospital, Professor Suo Xiaohui from Handan Central Hospital, Professor Li Lanfang from Tianjin Medical University Cancer Hospital, Professor Meng Xiangling from Cangzhou Integrated Traditional Chinese and Western Medicine Hospital, Professor Zhao Yue from the Fourth Hospital of Qinhuangdao City, and Professor Qiu Lihua from Tianjin Medical University Cancer Hospital made brief comments on the special report of the conference and had wonderful interactions with the speakers.
Conference summary Professor Zhang Huilai said that in recent years, the diagnosis and treatment of lymphoma has progressed rapidly, and the specialized construction and overall management of lymphoma in each center have been excellent.
Professor Zhang Huilai expects that Tianjin and other cancer hospitals and centers across the country can provide standardized diagnosis and treatment of lymphoma to benefit patients.
Finally, Professor Zhang Huilai expressed his gratitude to the experts and colleagues who participated in the meeting for their support and assistance, and congratulated the successful holding of the meeting.
Stamp "Read the original" to watch the replay of the conference
